clinical trial – Page 225 – Communicable Diseases Research

p38 MAPK inhibition: A promising therapeutic approach for COVID-19

Short communication

Published on 2020-07-012022-10-05
Journal: Journal of molecular and cellular cardiology [Category] SARS, 신약개발,

Anakinra in COVID-19: important considerations for clinical trials

Discussion

Published on 2020-07-012022-10-05
Journal: The Lancet Rheumatology [Category] 임상,

[키워드] Anakinra clinical trial
[DOI] 10.1016/S2665-9913(20)30160-0 [Article Type] Discussion

The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed

Correspondence

Published on 2020-07-012022-10-05
Journal: European journal of internal medicine [Category] SARS, 임상,

[키워드] clinical trial COVID-19 patient protocol reported Sample size SARS-CoV-2 Statistics trials
[DOI] 10.1016/j.ejim.2020.04.057 [Article Type] Correspondence

Pharmacotherapy in COVID-19; A narrative review for emergency providers

Review article

Published on 2020-07-012022-10-05
Journal: The American journal of emergency medicine [Category] SARS, 치료제,

[키워드] ACE ACE inhibitor active against acute respiratory distress angiotensin receptor blocker antagonist antimalarial Antiviral antivirals ARB ARBs ARDS Care Chloroquine Clinical guidelines clinical trial Combination combination treatment conducted convalescent plasma COVID 19 COVID-19 COVID-19 pandemic Critical CRS current current therapy Cytokine release syndrome develop disease drug Effectiveness Efficacy enzyme established therapy evaluated Evidence Favipiravir Fever Health Healthcare provider Hydroxychloroquine IL-6 information inhibitors lack literature review non-steroidal anti-inflammatory drug NSAIDS objective off-label pandemic Patient patients with moderate pharmacotherapy potential therapies professionals recommendation Remdesivir resource SARS-CoV-2 Septic shock syndrome systematic reviews therapeutic drug therapy Transmission Treatment treatment guidelines Trial
[DOI] 10.1016/j.ajem.2020.04.035 [Article Type] Review article

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험

Article

Published on 2020-07-012022-08-13
Journal: The Lancet. Infectious Diseases [Category] 임상,

[키워드] absence adverse event AID All participant All participants antibody Antigen Arabian Peninsula assigned baseline cellular cellular and humoral immunogenicity cellular response ChAdOx1 ChAdOx1 MERS clinical clinical development clinical trial coronavirus Department described dose dose-escalation doses effective elicit ELISA enzyme enzyme-linked immunospot expressing finding FIVE Follow-up follow-up period full-length full-length spike surface glycoprotein funding healthy hepatitis B hepatitis B surface antigen hepatitis C hepatitis C antibodies hepatitis C antibody High-dose high-dose group HIV antibodies humans humoral humoral immunogenicity IgG immunogenicity ImmunoSpot Infection interferon interferon-γ-linked enzyme-linked immunospot intermediate-dose group Intervention Intramuscular injection low-dose Medicine MERS MERS-CoV MERS-CoV spike antigen Middle East Middle East respiratory syndrome Coronavirus Mild mild in severity moderate neutralisation neutralisation assay Neutralising Antibodies nine Occurrence Open-label Oxford participant Phase 1 phase 1 trial pre-vaccination test pre-vaccination tests pregnancy test progression proportion Pseudotyped virus public health Registered Relative risk reported resolved respiratory respiratory syndrome coronavirus response risk Safe Safety Saudi Arabia Serious Adverse Event Serious Adverse Events severe adverse event significant increase significantly higher simian adenovirus-vectored vaccine single dose Support surface antigen Surface glycoprotein T-cell tested Tolerability trials tropical medicine urinary pregnancy test vaccination vectored vaccine Viral viral particle Viral particles virus neutralising assay virus neutralising assays was done women
[DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article

Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949

Review article

Published on 2020-07-012022-10-05
Journal: International journal of antimicrobial agents [Category] SARS, 임상,

[키워드] clinical trial non-randomized Open-label review Treatment
[DOI] 10.1016/j.ijantimicag.2020.106063 [Article Type] Review article

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies

Editorial

Published on 2020-07-012022-10-05
Journal: International Journal of Infectious Diseases [Category] SARS, 신약개발, 임상,

[키워드] agency antiviral drug blueprint cause caused Cell cellular circulating clinical clinical trial Combination combinations Community Consensus COVID-19 COVID-19 mortality death death rate disease effective HDTs Host host-directed therapy immune Inflammatory response initiated long-term functional disability MERS-CoV morbidity Mortality mortality rates MSC MSC therapy MSCs novel coronavirus disease ongoing trial pandemic pathogen pathogenesis of SARS-CoV-2 Patient reducing mortality regimen registry reported Repurposed drug severe COVID-19 disease specific treatment STEM the WHO therapeutic interventions therapy Treatment treatment trial Trial turn underlie Vaccine WHO WHO ICTRP World Health Organization
[DOI] 10.1016/j.ijid.2020.05.040 [Article Type] Editorial

Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis

Short communication

Published on 2020-07-012022-10-05
Journal: Gynecologic oncology [Category] 임상,

Is it ethically appropriate to continue surgical clinical trials during the COVID-19 pandemic?

Editorial

Published on 2020-07-012022-10-05
Journal: Surgery [Category] SARS, 임상,

[키워드] clinical trial COVID-19 surgical
[DOI] 10.1016/j.surg.2020.04.024 [Article Type] Editorial

A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

뮤신-1 감소 화합물에 대한 고함량 검사를 통해 포스타마티닙이 COVID-19 대유행 기간 동안 급성 폐 손상에 대한 신속한 용도 변경을 위한 후보로 확인됨

Article

Published on 2020-06-302022-09-11
Journal: bioRxiv [Category] 비임상,

[키워드] acute lung injury apical surface approved ARDS arising biochemical marker breath candidate Cell cell surface clinical development clinical outcomes clinical trial clinical trials Compound content COVID-19 pandemic distress drug drug candidate Drug repurposing Efficacy elevated epithelial cells expressed fostamatinib identify Immune thrombocytopenia inhibitor Lung disease lung epithelial cell Lung epithelial cells Lung injury membrane-bound mouse model MUC1 mucin mucosal pandemic pandemic spread Patient patients with COVID-19 predict promoted Protein provide R788 Rapid rationale reduce reduced repurposing required respiratory distress Respiratory distress syndrome reveal SARS-CoV-2 SARS-COV-2 infection Screen spleen Spread Stage standing up SYK syndrome the cell thrombocytopenia Treatment tyrosine
[DOI] 10.1101/2020.06.30.180380 PMC 바로가기 [Article Type] Article